Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study.
about
Translatability scoring in drug development: eight case studiesA systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulationParoxetine versus other anti-depressive agents for depressionAgomelatine versus other antidepressive agents for major depressionGetting the balance right: Established and emerging therapies for major depressive disordersAgomelatine: The evidence for its place in the treatment of depressionAdjunctive agomelatine therapy in the treatment of acute bipolar II depression: a preliminary open label studyInternational Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors.Review of pharmacological treatment in mood disorders and future directions for drug development.Profile of agomelatine and its potential in the treatment of generalized anxiety disorderAntidepressant efficacy of agomelatine: meta-analysis of published and unpublished studiesEfficacy of agomelatine in major depressive disorder: meta-analysis and appraisalEmerging targets for antidepressant therapiesAgomelatine adjunctive therapy for acute bipolar depression: preliminary open dataEfficacy of the novel antidepressant agomelatine for anxiety symptoms in major depressionIs there a role for agomelatine in the treatment of anxiety disorders?A review of published dataAgomelatine (S20098) modulates the expression of cytoskeletal microtubular proteins, synaptic markers and BDNF in the rat hippocampus, amygdala and PFCNovel targets for antidepressant therapiesAgomelatine in the treatment of major depressive disorder: an assessment of benefits and risksNew therapeutic targets for mood disordersBipolar disorder: candidate drug targets.Critical appraisal and update on the clinical utility of agomelatine, a melatonergic agonist, for the treatment of major depressive disease in adultsEfficacy and tolerability of agomelatine in the treatment of depressionBlockade of stress-induced increase of glutamate release in the rat prefrontal/frontal cortex by agomelatine involves synergy between melatonergic and 5-HT2C receptor-dependent pathwaysComparison of agomelatine and selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors in major depressive disorder: A meta-analysis of head-to-head randomized clinical trials.Melatonin agonists and insomnia.Hormone treatment of depression.A benefit-risk assessment of agomelatine in the treatment of major depression.New targets for rapid antidepressant action.Could agomelatine be the ideal antidepressant?Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder.Agomelatine treatment of major depressive disorder.Novel mechanism of antidepressant action: norepinephrine and dopamine disinhibition (NDDI) plus melatonergic agonism.Melatonin and its receptors: a new class of sleep-promoting agents.Combination of agomelatine and bupropion for treatment-resistant depression: results from a chart review study including a matched control group.Treatments in depression.Therapeutic potential of melatonin and its analogs in Parkinson's disease: focus on sleep and neuroprotection.Impact of maternal melatonin suppression on forced swim and tail suspension behavioral despair tests in adult offspring.Agomelatine: a novel antidepressant.Prospects for the treatment of depression.
P2860
Q22241760-10815B55-445B-478E-8184-737FEC177083Q22305782-F775F15F-629C-4EA9-B65B-1FC4F6359386Q24197507-0A6C3584-CAC5-428E-8512-9723CC4462FFQ24201746-AC236449-7994-45EF-8AC0-E84C980B858EQ24610225-52E00437-C182-4982-8057-0238F9CCFB6BQ24617019-3120523F-9858-4757-8D3C-85B474527CABQ24619584-99866A0E-1D05-41A9-8B15-BBE1A04B5F06Q24623433-278E7658-E8B4-41C5-9B35-E85190A013A2Q26853509-09CEE040-A3E4-42A6-9D69-96F57C5D2071Q26864049-AB06BFC7-394D-4FCA-825E-9F5EF3F870DCQ28236293-00626C59-8108-4BF3-A7E7-F71BA040AD61Q28246147-A10D6E26-4469-4E12-AB0F-3AE7C90F2BB5Q28247614-6A7222E0-EE72-4065-A1E6-D5E99CF3675DQ28248089-775CCB8B-08D4-4010-B713-177A43DDE035Q28287875-66944AB1-1E93-4EA8-9A60-1176E43E5BCBQ28292468-35836636-9E10-4728-898C-B30F4A80E6B2Q28578183-0EFE23D1-36A6-400E-AA24-1099A895EC28Q28648254-32F8CF0C-74E0-4140-84A4-B6B1F91E2897Q28651497-738F10AA-C332-4A47-A93C-405918AB5C28Q28743068-EF46A99B-9EAA-42EE-B88F-F23AB96E4DE6Q28751133-46983CFE-9529-43D7-BC5C-818699AD559FQ28764080-C9354D7D-B2F1-4525-9BF3-D872BF1A9A65Q33583450-C69B9C12-8E78-4A8F-ABCD-FEBFA26891C9Q33595018-041ED11E-2927-4D94-AACC-E5CAB13F8042Q34040072-5245F8EE-BE82-4155-9CC7-12AD7C36FAA9Q34097173-1ABDF420-F533-44A6-A307-028A403A2BC0Q34177698-44D82E54-1F79-4945-8EE9-7870D82FBF2CQ34207131-D8A7BD80-E55A-495B-A5F2-303A9DA51E25Q34507177-2C55BC39-143A-4367-BF5B-46FFFBF4167CQ34572999-AA0B752D-DAEC-478A-8089-E1458FD9DF29Q34579202-AAFD6B56-3849-4FAB-A58D-C15ADFDD4FFAQ34600886-3C10A309-CDA4-4BA2-86B6-2260CA51A115Q34660100-7207274A-F930-4C5C-B2DC-560FF4BDFAD6Q34682298-270E6ABB-2788-4A44-B137-C6B599535F73Q35169141-3192F550-7AFF-4E04-9B2A-900EFA225640Q35236696-7E203806-6EAC-4E41-844D-EB955474114DQ35276597-978CECE1-57CE-4AA2-8D33-25DCB75E2589Q35349799-EA2EB214-8A4B-429E-BB73-346046DA023AQ35628386-3E0859BC-1EC0-4988-A099-2E44A0463249Q36472992-3A3C9746-9ED8-4DFB-B5D8-3E75C6DCE5C2
P2860
Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study.
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Determination of the dose of a ...... o-controlled dose range study.
@ast
Determination of the dose of a ...... o-controlled dose range study.
@en
Determination of the dose of a ...... o-controlled dose range study.
@nl
type
label
Determination of the dose of a ...... o-controlled dose range study.
@ast
Determination of the dose of a ...... o-controlled dose range study.
@en
Determination of the dose of a ...... o-controlled dose range study.
@nl
prefLabel
Determination of the dose of a ...... o-controlled dose range study.
@ast
Determination of the dose of a ...... o-controlled dose range study.
@en
Determination of the dose of a ...... o-controlled dose range study.
@nl
P2093
P1476
Determination of the dose of a ...... o-controlled dose range study.
@en
P2093
P304
P356
10.1097/00004850-200209000-00004
P577
2002-09-01T00:00:00Z